SISCAPA Assay Technologies, Inc. filed a Form D with the Securities and Exchange Commission on 2025-08-28.
SISCAPA Assay Technologies, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 28, 2025. The filing reports $2M sold. Its industry group is Biotechnology. It names Norman Anderson (President, CEO), Constance Seniff (Secretary, Treasurer), Terry Pearson (Director) (SEC Form D, August 28, 2025).
In its own words: “SISCAPA® technology solves challenging protein measurement problems encountered in drug development, clinical trials and diagnostics.” (siscapa.com, checked November 1, 2026)
Is this your company?
Sell to companies like SISCAPA Assay Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns SISCAPA Assay Technologies, Inc.
Free to see. No signup.
More on the people and the money behind SISCAPA Assay Technologies, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when SISCAPA Assay Technologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when SISCAPA Assay Technologies, Inc. raises, hires or launches. No email unless you switch it on.
Watch SISCAPA Assay Technologies, Inc. →Get the full cited report on SISCAPA Assay Technologies, Inc.
What the filing shows about SISCAPA Assay Technologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on SISCAPA Assay Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives SISCAPA Assay Technologies, Inc.'s address as 1759 Willard St Nw, Washington, DC 20009.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on SISCAPA Assay Technologies, Inc. See pricing
SISCAPA Assay Technologies, Inc. is a registered filer with the SEC (CIK 1528248) and has filed since 2025-08-28. 1 filing is on record, the latest on 2025-08-28.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
SISCAPA Assay Technologies, Inc.'s Form D of 2025-08-28 names Norman Anderson, Constance Seniff, Terry Pearson and 1 more as its officers, directors or promoters.
Its new offerings report $2M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
On the filing as: Executive Officer, Director.
Norman Anderson is named as President, Ceo on the Form D that SISCAPA Assay Technologies, Inc. filed with the SEC on 28 August 2025, one of 4 people that filing names.
On the filing as: Executive Officer, Director.
Constance Seniff is named as Secretary, Treasurer on the Form D that SISCAPA Assay Technologies, Inc. filed with the SEC on 28 August 2025, one of 4 people that filing names.
Terry Pearson is named as Director on the Form D that SISCAPA Assay Technologies, Inc. filed with the SEC on 28 August 2025, one of 4 people that filing names.
Gus Salem is named as Director on the Form D that SISCAPA Assay Technologies, Inc. filed with the SEC on 28 August 2025, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2025-08-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about SISCAPA Assay Technologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on SISCAPA Assay Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SISCAPA Assay Technologies, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist SISCAPA Assay Technologies, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind SISCAPA Assay Technologies, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for SISCAPA Assay Technologies, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Washington, DC
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/siscapa-assay-technologies-inc-form-d-25000001